Brief: Nexcella Announces 50 Patients Already Treated With Car-T Nxc-201 Estimates 100-Patient Total Enrollment For FDA Approval BLA Submission
27/02/2023 13:47
Feb 27 (Reuters) - Immix Biopharma Inc IMMX.O :
* NEXCELLA ANNOUNCES 50 PATIENTS ALREADY TREATED WITH CAR-T
NXC-201; ESTIMATES 100-PATIENT TOTAL ENROLLMENT FOR U.S. FOOD
AND DRUG ADMINISTRATION APPROVAL BLA SUBMISSION
Source text for Eikon: ID:nGNE37YrMX
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary